Skip to main content

Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

Publication ,  Journal Article
Cloughesy, TF; Filka, E; Nelson, G; Kabbinavar, F; Friedman, H; Miller, LL; Elfring, GL
Published in: Am J Clin Oncol
April 2002

This phase II study was designed to evaluate the safety, tolerability, and efficacy of irinotecan (CPT-11) in the treatment of adults with malignant glioma. Patients with progressive or recurrent malignant gliomas were enrolled. CPT-11 was administered as a 90-minute intravenous infusion at a dose of 300 mg/m(2) once a week every 3 weeks. After 2 treatments, doses were increased to 350 mg/m(2) in those patients without grade III/IV toxicities. Dose modifications were made for toxicities. All 14 patients who enrolled (11 males and 3 females) were treated with CPT-11 and were assessable for survival, response, and toxicity. The majority of patients (86%) had prior surgery. Two patients had a confirmed partial response and 2 patients (14%) had stable disease. Median survival was 24 weeks. Median time to tumor progression was 6 weeks. The primary hematologic toxicity was grade III/IV neutropenia, which was observed in 14% of patients. Infrequent grade III/IV nonhematologic toxicity was observed, possibly because of the concomitant use of anticonvulsants, which may have altered pharmacokinetics. These results suggest that CPT-11 has activity against recurrent malignant glioma using a dosing regimen of 300 mg/m(2) every 3 weeks showing limited toxicity. The concurrent use of anticonvulsant medications may have played a role in altering pharmacokinetics and thus the maximum tolerated dose in this patient population.

Duke Scholars

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

April 2002

Volume

25

Issue

2

Start / End Page

204 / 208

Location

United States

Related Subject Headings

  • Topoisomerase I Inhibitors
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Irinotecan
  • Humans
  • Glioma
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cloughesy, T. F., Filka, E., Nelson, G., Kabbinavar, F., Friedman, H., Miller, L. L., & Elfring, G. L. (2002). Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol, 25(2), 204–208. https://doi.org/10.1097/00000421-200204000-00022
Cloughesy, Timothy F., Emese Filka, Gillian Nelson, Fairooz Kabbinavar, Henry Friedman, Langdon L. Miller, and Gary L. Elfring. “Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.Am J Clin Oncol 25, no. 2 (April 2002): 204–8. https://doi.org/10.1097/00000421-200204000-00022.
Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, et al. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol. 2002 Apr;25(2):204–8.
Cloughesy, Timothy F., et al. “Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.Am J Clin Oncol, vol. 25, no. 2, Apr. 2002, pp. 204–08. Pubmed, doi:10.1097/00000421-200204000-00022.
Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol. 2002 Apr;25(2):204–208.

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

April 2002

Volume

25

Issue

2

Start / End Page

204 / 208

Location

United States

Related Subject Headings

  • Topoisomerase I Inhibitors
  • Survival Analysis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Irinotecan
  • Humans
  • Glioma
  • Female